Roche group registers Phase III UC trial, GA-AMD study; AD extension stays active
Genentech and Hoffmann-La Roche logged a Phase III ulcerative colitis trial, a Phase II geographic atrophy study, and continued a long-term atopic dermatitis extension.
Three Roche-affiliated studies moved this week, spanning gastrointestinal, ophthalmic, and dermatologic programs.
- Hoffmann-La Roche, with collaborators Chugai Pharmaceutical and Pfizer, is recruiting for a Phase III trial of afimkibart (RO7790121) as subcutaneous induction therapy in moderately to severely active ulcerative colitis, named "AMETRINE-SC." The primary outcome measures the percentage of participants with clinical remission at Week 12.1 Enrollment is estimated at 350 participants1, and the record currently lists 1 site in 1 country: United States, Gastro One, Cordova, Tennessee (recruiting)1, with an estimated start date of 2026-11-15.
- Genentech registered a Phase II study of RO7965032 in geographic atrophy secondary to age-related macular degeneration. The study is listed as recruiting, with an estimated start date of 2027-01-08 and estimated primary completion of 2030-08-21.2 The primary outcomes include change in GA lesion area in the study eye and incidence and severity of ocular and non-ocular adverse events.2
- Hoffmann-La Roche's long-term extension study of afimkibart (RO7790121) in atopic dermatitis, called "Velarite-LTE," remains active but not recruiting. The study will assess long-term safety and efficacy of afimkibart in participants who took part in previous afimkibart clinical trials3, with an estimated enrollment of 120 participants.3
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.